№ lp_1_21637
File format: docx Character count: 9543 File size: 93 KB
This document outlines the responsibilities and procedures related to methotrexate use in the treatment of rheumatoid arthritis and psoriatic arthritis, detailing dosage, monitoring, and healthcare provider roles.
Note: Year
Theme: Rheumatology, Methotrexate Therapy, Drug Interaction
Document Type: Medical Guidelines
Target Audience: Healthcare Professionals, Specialists
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Request for Authorization of Treatment with STELARA® for Active Psoriatic Arthritis
Year: [Insert Year]
Region / City: [Insert City, State]
Subject: Authorization request for treatment with STELARA®
Document Type: Request for prior authorization
Organization: [Insert Payer Name]
Target Audience: Medical Director or individual responsible for prior authorization
Treatment Period: [Insert relevant time period if specified]
Approval Date: [Insert Date if available]
Amendment Date: [Insert Date if available]
Immunochip Genotyping and Statistical Quality Control Procedures for Psoriasis and Psoriatic Arthritis Association Analysis
Research field: Genetic epidemiology
Topic: Genetic association analysis of psoriasis and psoriatic arthritis
Document type: Research methods and supplementary materials description
Dataset: Immunochip dataset
Genotyping centres: Wellcome Trust Sanger Institute; Centre for Public Health Genomics at the University of Virginia; Arthritis Research UK Centre for Genetics and Genomics at the University of Manchester; University of Queensland Diamantina Institute; Trinity Translational Medicine at the University of Dublin
Genotyping software: GenomeStudio Data Analysis Software Platform (Genotyping Module v1.8.4)
Quality control tools: PLINK v1.07; EIGENSOFT v4.2; flashpca
Statistical methods: Identity-by-descent analysis; principal component analysis; logistic regression; Hardy–Weinberg equilibrium filtering
Genetic markers: SNPs from Immunochip array
Genomic region of interest: Major Histocompatibility Complex (MHC)
Genes analyzed: HLA-C; HLA-B; HLA-A
Phenotypes studied: Psoriasis; Psoriatic arthritis
Population reference datasets: HapMap3 CEU; CHB; JPT; YRI
Variables analyzed: Allele frequency; genotype call rate; heterozygosity; age of disease onset
Associated amino acid position: Position 45 of HLA-B
Summarising current Refractory Disease definitions in Rheumatoid Arthritis and Polyarticular Juvenile Idiopathic Arthritis: Systematic review
Year: 2021
Region / city: London, UK
Theme: Refractory Disease, Rheumatoid Arthritis, Juvenile Idiopathic Arthritis
Document type: Systematic review
Organization / institution: King’s College London
Authors: Hema Chaplin, Lewis Carpenter, Anni Raz, Elena Nikiphorou, Heidi Lempp, Sam Norton
Target audience: Medical professionals, researchers in rheumatology
Period of validity: Not applicable
Date of approval: Not stated
Date of amendments: 25.01.2021
Supplementary Materials and Statistical Analysis of Clinical and Laboratory Features in Rheumatoid Arthritis
Year: 2023
Region / City: N/A
Theme: Rheumatology, Clinical Research
Document Type: Research Supplementary Material
Institution: N/A
Author: N/A
Target Audience: Researchers, Healthcare Professionals
Period of Validity: N/A
Approval Date: N/A
Date of Changes: N/A
Inmedix - Revolutionizing Rheumatoid Arthritis Management with ANS Neuroscan™
Year: 2016
Region / city: Normandy Park, Washington
Subject: Rheumatoid Arthritis, Medical Technology
Document type: Company Overview
Organization: Inmedix
Author: Andrew J Holman, MD
Target audience: Healthcare professionals, pharmaceutical companies, investors
Period of action: 2016 and beyond
Approval date: October 2015
Date of changes: May 4, 2016
METHOTREXATE, Tablet 2.5 mg (as sodium) Tablet 10 mg (as sodium), Methoblastin®, PFIZER AUSTRALIA PTY LTD
Year: 2023
Region / city: Australia
Theme: Pharmaceutical submission
Document type: Pharmaceutical submission
Organization / institution: Pfizer Australia Pty Ltd
Author: Not specified
Target audience: Medical practitioners, nurse practitioners
Effective period: Not specified
Approval date: Not specified
Amendment date: Not specified
Context: Pharmaceutical submission requesting the inclusion of a new formulation of methotrexate under the General Schedule of the PBS for Australia, with changes in packaging and excipient composition.
Methotrexate (oral and subcutaneous) for adults in non-cancer services: HNY interim guidance 2025
Version: HNY v3.0
Replaces version: HNY v2.0
Clinical content last reviewed: November 2023
Next review date: July 2028
Local approval: 1st October 2025
Target population: Adults aged 18 and over, excluding cancer care
Indications: Licensed and off-label use in rheumatoid arthritis, Crohn’s disease, psoriasis, psoriatic arthritis, and other chronic inflammatory conditions
Administration routes: Oral, subcutaneous
Monitoring requirements: Blood tests, infection screening, vaccination advice, renal function assessment, pregnancy considerations
Responsible organizations: HNY ICB, RDTC
Document type: Shared Care Protocol
Contextual description: Clinical guidance source detailing licensed and off-label methotrexate indications, administration, monitoring, and transfer protocols between specialist and primary care for adults in non-cancer services.
Methotrexate, SOLUTION FOR SUBCUTANEOUS INJECTION, PREFILLED SYRINGE, 7.5 MG/0.15 ML, 10 MG/0.2 ML, 15 MG/0.3 ML, 20 MG/0.4 ML, 25 MG/0.5 ML, TREXJECT®
Year: 2023
Region / city: Australia
Topic: Rheumatology, Pharmaceutical Listings
Document type: Submission to Pharmaceutical Benefits Advisory Committee (PBAC)
Organization: Link Medical Products Pty Ltd
Author: Not specified
Target audience: Healthcare professionals, PBAC members
Period of validity: Not specified
Approval date: Not specified
Date of changes: Not specified
Note: Context
Service Specification for Methotrexate Monitoring (non-RheMOS patients only)
Year: 2017-2018
Region / City: Doncaster
Subject: Healthcare
Document Type: Service Specification
Organization: NHS
Author: Unknown
Target Audience: Healthcare Providers (GPs, Specialists)
Period of Validity: 1st April 2017 to 31st March 2018
Approval Date: Not specified
Date of Review: Annual
Clinical Commissioning Policy: Glucarpidase for urgent treatment of toxic plasma methotrexate concentration due to delayed methotrexate elimination, March 2024
Publication date: March 2024
Version: 3.0
First published: January 2015
Last updated: December 2022
Region: England
Type: Clinical commissioning policy
Organization: NHS England
Indication: Toxic plasma methotrexate concentration due to delayed methotrexate elimination
Target population: Adults and children receiving high-dose methotrexate chemotherapy
Therapeutic area: Oncology / Haematology
Administration: Urgent intravenous use
Expected annual use: 5–20 patients
Evidence base: Phase II studies, case reports, pooled compassionate-use trials
Risk assessment: Life-threatening methotrexate toxicity
Ethical framework: NHS healthcare commissioning principles, Individual Funding Request guidance
Topics: Psoriatic Rheumatoid METHOTREXATE